Key result
Dietary sphingolipids lower hepatic lipids, non-HDL cholesterol, and insulin levels in Zucker fatty rats.
Why the study?
The comparative effects of dietary sphingolipids with different chemical compositions on lipid metabolism and hepatic gene expression were not well characterized.
Do dietary sphingolipids ameliorate disorders of lipid metabolism in Zucker fatty rats?
Do dietary sphingolipids ameliorate disorders of lipid metabolism in Zucker fatty rats?
Dietary sphingolipids of different origins may prevent fatty liver and hypercholesterolemia through improved adiponectin signaling and insulin sensitivity in a preclinical model.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for sphingolipids in metabolic disease; human trials needed before clinical consideration.
Dietary sphingolipids (SL) inhibit colon carcinogenesis, reduce serum cholesterol, and improve skin barrier function and are considered to be "functional lipids". For comparative determination of the effects of SL with different chemical compositions on lipid metabolism and its related hepatic gene expression, Zucker fatty rats were fed pure sphingomyelin (SM) of animal origin and glucosylceramide (GC) of plant origin. After 45 days, the SM and GC diets led to significant reductions in hepatic lipid and plasma non-HDL cholesterol. Both SM and GC diets decreased plasma insulin levels, whereas only the GC diet increased the plasma adiponectin level. Hepatic gene expression analysis revealed increased expression of adiponectin receptor 2 (Adipor2), peroxisome proliferator-activated receptor alpha (PPARalpha), and pyruvate dehydrogenase kinase 4 (Pdk4). However, expression of stearoyl CoA desaturase (Scd1) was significantly decreased. These results suggest that dietary SL, even of different origins and chemical compositions, may prevent fatty liver and hypercholesterolemia through improvement of adiponectin signaling and consequent increases in insulin sensitivity.
No takes yet. Share an insight, caveat, or question.
Yunoki et al. (2010) studied Disorders of lipid metabolism. Dietary sphingolipids (sphingomyelin and glucosylceramide) was evaluated on Hepatic lipid and plasma non-HDL cholesterol levels. Dietary sphingolipids fed for 45 days significantly reduced hepatic lipid and plasma non-HDL cholesterol and decreased plasma insulin levels in Zucker fatty rats.
Synapse has enriched 10 related papers. Consider them for comparative context: